ClinicalTrials.gg
TerminatedNCT06415344Updated Nov 3, 2026

Long-term Extension of GTX-102 in Angelman Syndrome

A Phase 3 interventional study of GTX-102 in Angelman Syndrome, sponsored by Ultragenyx Pharmaceutical Inc. Terminated at 23 sites in 8 countries. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Ultragenyx Pharmaceutical Inc · Phase 3, Interventional, and Treatment

Why this study was terminated
Lack of efficacy
Updated Nov 3, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Angelman Syndrome with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Angelman Syndrome · United States.

Enrollment
15th of 24
66 · median 73
Started
2024
with 1 other
Phase 3
8 of 33
2 open now
Registered
26th of 33
by date
Lead sponsor
4 of 33
Ultragenyx Pharmaceutical Inc

Among the 33 studies in Angelman Syndrome with a site in United States, this one is the 15th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 in phase 3, and was the 26th registered.

Angelman Syndrome

52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.

Browse Angelman Syndrome studies →

Open to participants now

6 of the 33 studies in Angelman Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Angelman Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)

Read the detailed description

This study is a phase 3, long term extension (LTE) which is open to participants rolling over from a prior GTX-102 clinical study. The LTE study will evaluate the long-term safety and efficacy of GTX-102 in participants with AS.

03

Conditions studied

  • Angelman Syndrome

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed from parent(s) or legal guardian(s).
  • Completed a final study visit in a prior clinical trial with GTX-102. If the subject has an ongoing adverse event, medical monitor approval is required to rollover. The Screening visit must occur within 6 months of the last visit in the prior GTX-102 trial.
  • From the time of informed consent through the end of the study and for at least 6 months after the final dose of GTX-102, females of who are sexually active must use highly effective or abstinence. Males are able to participate if they agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the study and for at least 3 months after the final dose of GTX-102.

Exclusion criteria

Exclusion Criteria:

  • Discontinued from study or withdrew from study treatment in a prior GTX-102 trial.
  • History or evidence of any other medical, neurological, or psychological condition that would expose the subject to an undue risk of a significant AE or interfere with study assessments during the course of the trial as determined by the clinical judgment of the Investigator.
  • Known to GTX-102 or its that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.
  • Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    GTX-102

    Participants will receive GTX-102 via intrathecal lumbar puncture (IT LP) on a intrapatient flexible dosing schedule.

    Drug: GTX-102

Interventions

  • Antisense Oligonucleotide

    Also known as: apazunersen

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 5 Years

Secondary outcomes

  1. Change from Baseline in the Bayley-4 Raw Score

    Time frame: Baseline, Up to 5 Years

  2. Net Response in Multidomain Responder Index (MDRI)

    Time frame: Month 12, Month 24

07

Study locations

23 sites
  • University of California, Los Angeles (UCLA)
    Los Angeles, California 90095, United States
  • University of California, San Diego - Rady Children's Hospital
    San Diego, California 92123, United States
  • Rare Disease Research, LLC
    Atlanta, Georgia 30329, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Weill Cornell Medicine
    New York, New York 10021, United States
  • Queensland Children's Hospital
    South Brisbane, Queensland 4101, Australia
  • The Royal Children's Hospital
    Melbourne, Victoria 3052, Australia
  • MAGIC Clinic Ltd
    Calgary, Alberta T2E 7Z4, Canada
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
  • Childrens Hospital London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Childrens Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • The Research Institute of the McGill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
  • AP-HM - Hopital de la Timone
    Marseille, 13385, France
  • AP-HP Hopital Necker-Enfants Malades
    Paris, 75015, France
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Hospital Universitario Puerta de Hierro
    Majadahonda, 28222, Spain
  • Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
    Sabadell, 08208, Spain
  • University of Cambridge
    Cambridge, CB2 0QQ, United Kingdom
  • Great Ormond Street Hospital for Children
    London, WC1N 3JH, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, OX3 9DU, United Kingdom
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2024 to primary completion in Oct 2026, 26 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Feb 2029 → Oct 2026 and completion Feb 2029 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 16, 2024
StartActual
Jul 31, 2024
Primary completionActual
Oct 30, 2026was Feb 2029
CompletionActual
Oct 30, 2026was Feb 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Lack of efficacy
changed Nov 3, 2026
Primary completion
Feb 2029→Oct 30, 2026 (actual)
Nov 3, 2026
Study completion
Feb 2029→Oct 30, 2026 (actual)
Nov 3, 2026
Enrollment
255 (estimated)→66 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Terminated
    Why stopped Lack of efficacy
    Primary completion Feb 2029→Oct 30, 2026 (now actual)
    Study completion Feb 2029→Oct 30, 2026 (now actual)
    Enrollment 255 (estimated)→66 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06415344
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Jul 31, 2024
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 3, 2026

Study contacts

Medical Director
study director · Ultragenyx Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apazunersen sodium

Start the discussion